Mirez 15 mg (Tablet)

Indications

• Treatment of major depressive disorder (MDD)

Pharmacology

• Enhances central noradrenergic and serotonergic activity
• Antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors
• Antagonist of 5-HT₂ and 5-HT₃ receptors
• Potent antagonist of histamine (H₁) receptors
• Moderate peripheral α1-adrenergic antagonist
• Moderate antagonist at muscarinic receptors

Dosage & Administration

• Recommended starting dose of 15 mg/day
• Effective dose range of 15 to 45 mg/day
• Elimination half-life of 20 to 40 hours
• Dose changes should be made at intervals of less than 1 to 2 weeks

Interaction

• Clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs
• May interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine
• Patient should avoid Alcohol & Diazepam

Contraindications

• Contraindicated in patients with known hypersensitivity to Mirtazapine or to any of the excipients
• Concomitant use with a monoamine oxidase (MAO) inhibitor is contraindicated

Side Effects

• Dizziness
• Drowsiness
• Dry mouth
• Increased appetite
• Weight gain

Pregnancy & Lactation

• Pregnancy Category-C
• Patients should notify physician if they become pregnant or intend to become pregnant during therapy
• Patients should notify physician if they are breastfeeding an infant

Precautions & Warnings

• Patients, families, and caregivers should be alert to the emergence of certain behaviors
• Warned about the risk of developing agranulocytosis
• May impair judgment, thinking, and motor skills
• Clinically significant ALT (SGPT) elevations may occur

Therapeutic Class

• Atypical anti-depressant drugs

Storage Conditions

• Keep away from light and moisture
• Store below 30º C
• Keep all medicine out of the reach of children

Related Brands

• Mirapin 15 mg (Tablet) - beacon-pharmaceuticals-plc
• Mirtaz 15 mg (Tablet) - sun-pharmaceutical-bangladesh-ltd